Cargando…

Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1

Background  Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder that increases the risk of developing benign and malignant tumors. Several associated endocrine diseases in NF-1 patients have been explained in the literature. Thus, this study aims to assess the endocrine...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshahrani, Aysha, Abuoliat, Zainah, Alshahrani, Awad Saad, Al Balwi, Mohammed Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110103/
https://www.ncbi.nlm.nih.gov/pubmed/35586386
http://dx.doi.org/10.1055/s-0041-1742197
_version_ 1784709027191586816
author Alshahrani, Aysha
Abuoliat, Zainah
Alshahrani, Awad Saad
Al Balwi, Mohammed Ali
author_facet Alshahrani, Aysha
Abuoliat, Zainah
Alshahrani, Awad Saad
Al Balwi, Mohammed Ali
author_sort Alshahrani, Aysha
collection PubMed
description Background  Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder that increases the risk of developing benign and malignant tumors. Several associated endocrine diseases in NF-1 patients have been explained in the literature. Thus, this study aims to assess the endocrine manifestations as there no previous local data have discussed this association. Methods  A retrospective cross-sectional study was conducted at KAMC and KASCH, Riyadh, Saudi Arabia by including all patients genetically confirmed with NF1 from 2004 until 2019 using a consecutive non-probability sampling technique. The included data were demographics, consanguinity, genetic variant mutations as well as associated endocrine diseases. Results  The prevalence of patients with associated endocrine diseases was estimated to be 19.4%. Short stature showed the highest frequency of associated endocrine diseases followed by subclinical hypothyroidism. Positive consanguinity, sporadic mutation, and pathogenic variant showed high frequencies. Conclusion  The coexistence of endocrine diseases was found in NF-1 patients. Therefore, screening for endocrine abnormality in patients with NF-1 by comprehensive history and physical exam as well as investigations to minimize complications and the late presentation should be considered; however, further studies are necessary to address the need.
format Online
Article
Text
id pubmed-9110103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-91101032022-05-17 Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1 Alshahrani, Aysha Abuoliat, Zainah Alshahrani, Awad Saad Al Balwi, Mohammed Ali Avicenna J Med Background  Neurofibromatosis type 1 (NF-1) is an autosomal dominant neurocutaneous disorder that increases the risk of developing benign and malignant tumors. Several associated endocrine diseases in NF-1 patients have been explained in the literature. Thus, this study aims to assess the endocrine manifestations as there no previous local data have discussed this association. Methods  A retrospective cross-sectional study was conducted at KAMC and KASCH, Riyadh, Saudi Arabia by including all patients genetically confirmed with NF1 from 2004 until 2019 using a consecutive non-probability sampling technique. The included data were demographics, consanguinity, genetic variant mutations as well as associated endocrine diseases. Results  The prevalence of patients with associated endocrine diseases was estimated to be 19.4%. Short stature showed the highest frequency of associated endocrine diseases followed by subclinical hypothyroidism. Positive consanguinity, sporadic mutation, and pathogenic variant showed high frequencies. Conclusion  The coexistence of endocrine diseases was found in NF-1 patients. Therefore, screening for endocrine abnormality in patients with NF-1 by comprehensive history and physical exam as well as investigations to minimize complications and the late presentation should be considered; however, further studies are necessary to address the need. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-02-18 /pmc/articles/PMC9110103/ /pubmed/35586386 http://dx.doi.org/10.1055/s-0041-1742197 Text en Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Alshahrani, Aysha
Abuoliat, Zainah
Alshahrani, Awad Saad
Al Balwi, Mohammed Ali
Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
title Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
title_full Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
title_fullStr Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
title_full_unstemmed Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
title_short Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1
title_sort prevalence of associated endocrine diseases in patients with neurofibromatosis type 1
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110103/
https://www.ncbi.nlm.nih.gov/pubmed/35586386
http://dx.doi.org/10.1055/s-0041-1742197
work_keys_str_mv AT alshahraniaysha prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1
AT abuoliatzainah prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1
AT alshahraniawadsaad prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1
AT albalwimohammedali prevalenceofassociatedendocrinediseasesinpatientswithneurofibromatosistype1